Profound Medical to Release First Quarter 2025 Financial Results on May 8 – Conference Call to Follow
Profound Medical (NASDAQ: PROF; TSX: PRN), a commercial-stage medical device company focused on developing incision-free ablation therapies, has scheduled its first quarter 2025 financial results announcement for May 8, 2025, after market close.
The company will host a conference call at 4:30 p.m. ET on the same day, where management will review financial results and discuss business developments from the period. Investors can access the live call through registration and the broadcast will be archived on the company's website under the Investors section.
Profound Medical (NASDAQ: PROF; TSX: PRN), un'azienda di dispositivi medici in fase commerciale specializzata nello sviluppo di terapie di ablazione senza incisioni, ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 per il 8 maggio 2025, dopo la chiusura del mercato.
La società terrà una conference call alle 16:30 ET dello stesso giorno, durante la quale il management esaminerà i risultati finanziari e discuterà gli sviluppi aziendali del periodo. Gli investitori potranno partecipare alla chiamata in diretta registrandosi, e la trasmissione sarà archiviata nella sezione Investitori del sito web dell'azienda.
Profound Medical (NASDAQ: PROF; TSX: PRN), una empresa de dispositivos médicos en etapa comercial enfocada en desarrollar terapias de ablación sin incisiones, ha programado el anuncio de resultados financieros del primer trimestre de 2025 para el 8 de mayo de 2025, después del cierre del mercado.
La compañía realizará una conferencia telefónica a las 4:30 p.m. ET del mismo día, donde la dirección revisará los resultados financieros y discutirá los desarrollos comerciales del período. Los inversores podrán acceder a la llamada en vivo mediante registro y la transmisión quedará archivada en la sección de Inversores en la página web de la empresa.
Profound Medical (NASDAQ: PROF; TSX: PRN)은 절개 없는 소작 치료법 개발에 집중하는 상업 단계 의료기기 회사로, 2025년 1분기 재무 실적 발표를 2025년 5월 8일 장 마감 후에 예정하고 있습니다.
회사는 같은 날 동부 표준시 오후 4시 30분에 컨퍼런스 콜을 진행하며, 경영진이 재무 실적을 검토하고 해당 기간의 사업 현황을 논의할 예정입니다. 투자자들은 사전 등록을 통해 라이브 콜에 참여할 수 있으며, 방송은 회사 웹사이트 투자자 섹션에 아카이브됩니다.
Profound Medical (NASDAQ : PROF ; TSX : PRN), une entreprise de dispositifs médicaux en phase commerciale spécialisée dans le développement de thérapies d’ablation sans incision, a prévu l'annonce des résultats financiers du premier trimestre 2025 pour le 8 mai 2025, après la clôture du marché.
La société tiendra une conférence téléphonique à 16h30 ET le même jour, au cours de laquelle la direction présentera les résultats financiers et discutera des développements commerciaux de la période. Les investisseurs pourront accéder à l’appel en direct via inscription, et la diffusion sera archivée dans la section Investisseurs du site web de l’entreprise.
Profound Medical (NASDAQ: PROF; TSX: PRN), ein Unternehmen für medizinische Geräte in der kommerziellen Phase, das sich auf die Entwicklung von schnittfreien Ablationstherapien spezialisiert hat, hat die Veröffentlichung der Finanzergebnisse für das erste Quartal 2025 für den 8. Mai 2025 nach Börsenschluss geplant.
Das Unternehmen wird am selben Tag um 16:30 Uhr ET eine Telefonkonferenz abhalten, in der das Management die Finanzergebnisse bespricht und die geschäftlichen Entwicklungen des Zeitraums erläutert. Investoren können über eine Registrierung an dem Live-Call teilnehmen, und die Übertragung wird im Investor-Bereich der Unternehmenswebsite archiviert.
- None.
- None.
TORONTO, April 17, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its first quarter 2025 financial results after market close on Thursday, May 8, 2025.
Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period.
First Quarter 2025 Results Conference Call Details:
Date: Thursday, May 8, 2025
Time: 4:30 p.m. ET
Live Call Registration: https://register-conf.media-server.com/register/BI2ca675b1f05d401a815d65a4885241c6
The call will also be broadcast live and archived on the Company's website at www.profoundmedical.com under "Webcasts" in the Investors section.
About Profound Medical Corp.
Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.
Profound is commercializing TULSA-PRO®, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO® system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (“BPH”); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. TULSA employs real-time MR guidance for precision to preserve patients’ urinary continence and sexual function, while killing the targeted prostate tissue via precise sound absorption technology that gently heats it to 55-57°C. TULSA is an incision- and radiation-free “one-and-done” procedure performed in a single session that takes a few hours. Virtually all prostate shapes and sizes can be safely, effectively, and efficiently treated with TULSA. There is no bleeding associated with the procedure; no hospital stay is required; and most TULSA patients report quick recovery to their normal routine. TULSA-PRO® is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (“FDA”).
Profound is also commercializing Sonalleve®, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. Sonalleve® has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a Humanitarian Device Exemption for the treatment of osteoid osteoma. The Company is in the early stages of exploring additional potential treatment markets for Sonalleve® where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.
For further information, please contact:
Stephen Kilmer
Investor Relations
skilmer@profoundmedical.com
T: 647.872.4849
FAQ
When will Profound Medical (PROF) release Q1 2025 earnings?
How can investors join Profound Medical's Q1 2025 earnings call?
Where can I find the replay of Profound Medical's Q1 2025 earnings call?
What time is Profound Medical's (PROF) Q1 2025 earnings call?
